Target and tissue selectivity of PROTAC degraders

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Drug Discovery

Background:

• Traditional small molecule inhibitors face limitations in selectivity and tissue targeting.
• Undruggable proteins present significant challenges in therapeutic development.
• Targeted protein degradation (TPD) offers a novel approach to protein inhibition.

Purpose of the Study:

• To review recent advancements in creating selective proteolysis targeting chimeras (PROTACs).
• To analyze new PROTAC technologies for enhanced target selectivity.
• To discuss the implications of selective TPD for treating diseases.

Main Methods:

• Analysis of PROTAC linker optimization for selectivity.
• Investigation of ternary complex stabilization in PROTAC efficacy.
• Exploitation of E3 ligase tissue-specific activity for targeted degradation.

Main Results:

• PROTACs demonstrate improved target selectivity beyond parent ligands.
• Linker length and ternary complex dynamics are key to PROTAC selectivity.
• E3 ligase properties enable novel tissue-specific targeting strategies.

Conclusions:

• Selective PROTAC development is advancing rapidly.
• New PROTAC technologies expand the scope of druggable targets.
• Selective TPD holds significant promise for future disease therapies, including for previously undruggable proteins.